{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T09:58:16Z","timestamp":1777111096472,"version":"3.51.4"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cardiovascular Revascularization Medicine"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.carrev.2021.09.010","type":"journal-article","created":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T17:39:13Z","timestamp":1632937153000},"page":"73-83","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Hemopericardium in the Setting of Direct Oral Anticoagulant Use: An Updated Systematic Review"],"prefix":"10.1016","volume":"39","author":[{"given":"Abu Baker","family":"Sheikh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ishan","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shazib","family":"Sagheer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nismat","family":"Javed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdul Mannan Khan","family":"Minhas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erick Daniel","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charmy","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahul","family":"Shekhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.carrev.2021.09.010_bb0005","first-page":"e199","article-title":"AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society","volume":"130","author":"January","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2021.09.010_bb0010","doi-asserted-by":"crossref","unstructured":"Chen A, Stecker E, A Warden B. Direct oral anticoagulant use: a practical guide to common clinical challenges. J Am Heart Assoc 2020;9:e017559. doi:https:\/\/doi.org\/10.1161\/JAHA.120.017559.","DOI":"10.1161\/JAHA.120.017559"},{"key":"10.1016\/j.carrev.2021.09.010_bb0015","doi-asserted-by":"crossref","first-page":"40","DOI":"10.15420\/ecr.2017:11:2","article-title":"Direct Oral anticoagulants: a quick guide","volume":"12","author":"Julia","year":"2017","journal-title":"Eur Cardiol"},{"key":"10.1016\/j.carrev.2021.09.010_bb0020","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1016\/j.ijcard.2014.04.151","article-title":"Life-threatening haemorrhagic pericarditis associated with rivaroxaban","volume":"174","author":"Xu","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.carrev.2021.09.010_bb0025","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1136\/bmjebm-2017-110853","article-title":"Methodological quality and synthesis of case series and case reports","volume":"23","author":"Murad","year":"2018","journal-title":"BMJ Evid Based Med"},{"key":"10.1016\/j.carrev.2021.09.010_bb0030","doi-asserted-by":"crossref","first-page":"249","DOI":"10.14740\/cr902","article-title":"Spontaneous hemorrhagic pericardial and pleural effusion in a patient receiving apixaban","volume":"10","author":"Cinelli","year":"2019","journal-title":"Cardiol Res"},{"key":"10.1016\/j.carrev.2021.09.010_bb0035","article-title":"A possible drug-drug interaction between eliquis and amiodarone resulting in hemopericardium","volume":"13","author":"Olagunju","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.carrev.2021.09.010_bb0040","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s11739-017-1736-3","article-title":"Cardiac tamponade due to apixaban therapy in patient with unknown pericardial hemangioma","volume":"13","author":"Sbrana","year":"2018","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.carrev.2021.09.010_bb0045","doi-asserted-by":"crossref","first-page":"e768","DOI":"10.1097\/MJT.0000000000000775","article-title":"Cardiovascular side effects of tyrosine kinase inhibitor ibrutinib (Imbruvica) and interaction with direct oral anticoagulant","volume":"25","author":"Khalid","year":"2018","journal-title":"Am J Ther"},{"key":"10.1016\/j.carrev.2021.09.010_bb0050","first-page":"A5180","article-title":"Is it safe? A case of apixaban use in peritoneal dialysis","volume":"201","author":"Jiwani","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.carrev.2021.09.010_bb0055","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.carrev.2019.04.002","article-title":"Hemorrhagic cardiac tamponade associated with apixaban: a case report and systematic review of literature","volume":"20","author":"Asad","year":"2019","journal-title":"Cardiovasc Revasc Med"},{"key":"10.1016\/j.carrev.2021.09.010_bb0060","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.hrcr.2017.11.015","article-title":"First reported case series in the United States of hemopericardium in patients on apixaban","volume":"4","author":"Sablani","year":"2017","journal-title":"HeartRhythm Case Rep"},{"key":"10.1016\/j.carrev.2021.09.010_bb0065","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1002\/phar.1602","article-title":"Spontaneous hemopericardium in a patient receiving apixaban therapy: first case report","volume":"35","author":"Sigawy","year":"2015","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.carrev.2021.09.010_bb0070","article-title":"Acute haemorrhagic tamponade in cancer patients receiving direct oral anticoagulant: case series","volume":"1","author":"Nassif","year":"2017","journal-title":"Eur Heart J Case Rep"},{"key":"10.1016\/j.carrev.2021.09.010_bb0075","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ijscr.2020.10.090","article-title":"Case report of simultaneous presentation of pulmonary embolism and pericardial effusion following an oncological esophagectomy","volume":"77","author":"Jou-Valencia","year":"2020","journal-title":"Int J Surg Case Rep"},{"key":"10.1016\/j.carrev.2021.09.010_bb0080","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.4081\/cp.2019.1096","article-title":"Isolated hemopericardium after initiation of rivaroxaban: implications and potential mechanisms","volume":"9","author":"Mehta","year":"2019","journal-title":"Clin Pract"},{"key":"10.1016\/j.carrev.2021.09.010_bb0085","first-page":"1650716","article-title":"A rare case of spontaneous cardiac tamponade induced by concomitant use of rivaroxaban and amiodarone","volume":"2018","author":"Oladiran","year":"2018","journal-title":"Case Rep Cardiol"},{"key":"10.1016\/j.carrev.2021.09.010_bb0090","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1002\/phar.1474","article-title":"Isolated hemopericardium associated with rivaroxaban: first case report","volume":"34","author":"Shivamurthy","year":"2014","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.carrev.2021.09.010_bb0095","first-page":"414","article-title":"Hemopericardium with tamponade following rivaroxaban administration and its attenuation by CYP3A4 inhibitors","volume":"29","author":"Menendez","year":"2016","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"10.1016\/j.carrev.2021.09.010_bb0100","doi-asserted-by":"crossref","unstructured":"Basnet S, Tachamo N, Tharu B, Dhital R, Ghimire S, Poudel DR. Life-threatening Hemopericardium associated with rivaroxaban. Case Rep Cardiol 2017; 2017:4691325. doi:https:\/\/doi.org\/10.1155\/2017\/4691325.","DOI":"10.1155\/2017\/4691325"},{"key":"10.1016\/j.carrev.2021.09.010_bb0105","doi-asserted-by":"crossref","first-page":"138","DOI":"10.12793\/tcp.2017.25.3.138","article-title":"Hemorrhagic pericarditis associated with rivaroxaban in an atrial fibrillation patient with pacemaker","volume":"25","author":"Rhew","year":"2017","journal-title":"Transl Clin Pharmacol"},{"key":"10.1016\/j.carrev.2021.09.010_bb0110","first-page":"1015","article-title":"Rivaroxaban and hemopericardium \u2013 is there an association?","volume":"2","author":"Gowani","year":"2017","journal-title":"Austin Cardio & Cardiovasc Case Rep"},{"key":"10.1016\/j.carrev.2021.09.010_bb0115","doi-asserted-by":"crossref","DOI":"10.31160\/JOTCI201927A20180006","article-title":"Spontaneous hemopericardium and cardiac tamponade induced by dabigatran in combination with p-glycoprotein inhibitor","volume":"27","author":"Salas","year":"2019","journal-title":"J Transcat Intervent"},{"key":"10.1016\/j.carrev.2021.09.010_bb0120","doi-asserted-by":"crossref","first-page":"155","DOI":"10.5671\/ca.44.3.7","article-title":"Dabigatran use associated with hemopericardium and hemothorax","volume":"44","author":"Kati\u0107","year":"2020","journal-title":"Coll Antropol"},{"key":"10.1016\/j.carrev.2021.09.010_bb0125","first-page":"27","article-title":"Use of idarucizumab for dabigatran reversal in cardiac tamponade during atrial fibrillation ablation: a case report","volume":"20","author":"Yoshizawa","year":"2019","journal-title":"J Cardiol Cases"},{"key":"10.1016\/j.carrev.2021.09.010_bb0130","first-page":"310","article-title":"Dabigatran-induced hemopericardium with tamponade","volume":"23","author":"Bitar","year":"2020","journal-title":"Crit Care Shock"},{"key":"10.1016\/j.carrev.2021.09.010_bb0135","doi-asserted-by":"crossref","first-page":"370","DOI":"10.14503\/THIJ-16-6073","article-title":"Dabigatran-induced spontaneous hemopericardium and cardiac tamponade","volume":"44","author":"Jelani","year":"2017","journal-title":"Tex Heart Inst J"},{"key":"10.1016\/j.carrev.2021.09.010_bb0140","doi-asserted-by":"crossref","first-page":"99","DOI":"10.4070\/kcj.2016.46.1.99","article-title":"Hemopericardium and cardiac tamponade in a patient treated with dabigatran etexilate","volume":"46","author":"Kizilirmak","year":"2016","journal-title":"Korean Circ J"},{"key":"10.1016\/j.carrev.2021.09.010_bb0145","doi-asserted-by":"crossref","first-page":"179","DOI":"10.5530\/jcdr.2015.4.3","article-title":"Spontaneous hemopericardium with dabigatran etexilate","volume":"6","author":"Masoomi","year":"2015","journal-title":"J Cardiovasc Dis Res"},{"key":"10.1016\/j.carrev.2021.09.010_bb0150","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1002\/j.1875-9114.2012.01036.x","article-title":"Hemopericardium in a patient treated with dabigatran etexilate","volume":"32","author":"Barton","year":"2012","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.carrev.2021.09.010_bb0155","doi-asserted-by":"crossref","DOI":"10.1345\/aph.1R112","article-title":"Hemopericardium and cardiac tamponade associated with dabigatran use","volume":"46","author":"Dy","year":"2012","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.carrev.2021.09.010_bb0160","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.hrcr.2019.12.003","article-title":"Life-threatening pericardial bleed complicating atrial fibrillation ablation associated with edoxaban therapy successfully managed with prothrombin complex concentrate","volume":"6","author":"Choudhury","year":"2019","journal-title":"HeartRhythm Case Rep"},{"key":"10.1016\/j.carrev.2021.09.010_bb0165","first-page":"342","article-title":"Spontaneous hemopericardium complicated with hemothorax in a patient receiving edoxaban therapy: a case report","volume":"35","author":"Tsai","year":"2019","journal-title":"Acta Cardiol Sin"},{"key":"10.1016\/j.carrev.2021.09.010_bb0170","first-page":"161","article-title":"Spontaneous hemopericardium as an adverse effect of rivaroxaban administration","volume":"6","author":"Surani","year":"2019","journal-title":"Int J Clin Cardiol"},{"key":"10.1016\/j.carrev.2021.09.010_bb0175","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.hrtlng.2015.02.006","article-title":"A sanguineous pleuro pericardial effusion in a patient recently treated with Dabigatran","volume":"44","author":"Abdallah","year":"2015","journal-title":"Heart Lung"},{"key":"10.1016\/j.carrev.2021.09.010_bb0180","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/MBC.0000000000000553","article-title":"Hemopericardium under dabigatran for stroke prevention in atrial fibrillation","volume":"28","author":"St\u00f6llberger","year":"2017","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.carrev.2021.09.010_bb0185","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.chest.2017.03.050","article-title":"IVIg for treatment of severe refractory heparin-induced thrombocytopenia","volume":"152","author":"Padmanabhan","year":"2017","journal-title":"Chest"},{"key":"10.1016\/j.carrev.2021.09.010_bb0190","doi-asserted-by":"crossref","first-page":"e1128","DOI":"10.1097\/MJT.0000000000000263","article-title":"Life-threatening hemorrhagic cardiac tamponade secondary to rivaroxaban","volume":"23","author":"Kham","year":"2016","journal-title":"Am J Ther"},{"key":"10.1016\/j.carrev.2021.09.010_bb0195","author":"EMResident"},{"key":"10.1016\/j.carrev.2021.09.010_bb0200","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1053\/j.seminhematol.2014.03.007","article-title":"Direct oral anticoagulants\u2014interference with laboratory tests and mechanism of action","volume":"51","author":"Tsakiris","year":"2014","journal-title":"Semin Hematol"},{"key":"10.1016\/j.carrev.2021.09.010_bb0205","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/17425255.2019.1604686","article-title":"Pharmacokinetics and pharmacodynamics of oral anticoagulants used in atrial fibrillation","volume":"15","author":"Fawzy","year":"2019","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.carrev.2021.09.010_bb0210","doi-asserted-by":"crossref","unstructured":"Luettgen JM, Bozarth TA, Bozarth JM, Barbera FA, Lam PY, Quan ML, PhD, et al. In vitro evaluation of apixaban, a novel, potent, selective and orally bioavailable factor Xa inhibitor. Blood (ASH Annual Meeting Abstracts) 2006; 108:4130. doi:https:\/\/doi.org\/10.1182\/blood.V108.11.4130.4130.","DOI":"10.1182\/blood.V108.11.4130.4130"},{"key":"10.1016\/j.carrev.2021.09.010_bb0215","doi-asserted-by":"crossref","first-page":"5339","DOI":"10.1021\/jm070245n","volume":"50","author":"Pinto","year":"2007","journal-title":"J Med Chem"},{"key":"10.1016\/j.carrev.2021.09.010_bb0220","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/j.1365-2125.2012.04369.x","article-title":"Apixaban, an oral direct factor Xa inhibitor: multiple-dose safety, pharmacokinetics, and pharmacodynamics in healthy subjects","volume":"75","author":"Frost","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.carrev.2021.09.010_bb0225","first-page":"1862","article-title":"In vitro characteristics, anticoagulant effects and in vivo antithrombotic efficacy of a novel, potent and orally active direct factor Xa inhibitor, DU-176b","volume":"104","author":"Morishima","year":"2004","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.carrev.2021.09.010_bb0230","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1160\/TH07-04-0312","article-title":"Antithrombotic effects of factor Xa inhibition with DU-176b: phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber","volume":"98","author":"Zafar","year":"2007","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.carrev.2021.09.010_bb0235","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1111\/j.1538-7836.2008.03064.x","article-title":"DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles","volume":"6","author":"Furugohri","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.carrev.2021.09.010_bb0240","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2016-215731","article-title":"Bleeding heart: a case of spontaneous hemopericardium and tamponade in a hyperthyroid patient on warfarin","volume":"2016","author":"Sajawal Ali","year":"2016","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.carrev.2021.09.010_bb0245","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3949\/ccjm.60.4.336","article-title":"Hemopericardium and cardiac tamponade associated with warfarin therapy","volume":"60","author":"Lee","year":"1993","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.carrev.2021.09.010_bb0250","first-page":"115","article-title":"Hemopericardium and cardiac tamponade in a patient with an elevated international normalized ratio","volume":"10","author":"Levis","year":"2009","journal-title":"West J Emerg Med"},{"key":"10.1016\/j.carrev.2021.09.010_bb0255","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1136\/emj.2007.049643","article-title":"Cardiac tamponade secondary to haemopericardium in a patient on warfarin","volume":"24","author":"Hong","year":"2007","journal-title":"Emerg Med J"},{"key":"10.1016\/j.carrev.2021.09.010_bb0260","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1056\/NEJM196504012721305","article-title":"Anticoagulant-induced hemopericardium with tamponade: its occurrence in the absence of myocardial infarction or pericarditis","volume":"272","author":"Fell","year":"1965","journal-title":"N Engl J Med"},{"key":"10.1016\/j.carrev.2021.09.010_bb0265","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1159\/000207006","article-title":"Spontaneous anticoagulant-induced hemopericardium with tamponade","volume":"68","author":"Granot","year":"1982","journal-title":"Acta Haematol"},{"key":"10.1016\/j.carrev.2021.09.010_bb0270","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1017\/S148180350001321X","article-title":"Atraumatic hemopericardium in a patient receiving warfarin therapy for a pulmonary embolus","volume":"7","author":"Katis","year":"2005","journal-title":"CJEM"},{"key":"10.1016\/j.carrev.2021.09.010_bb0275","doi-asserted-by":"crossref","unstructured":"Al-Jundi W, Rubin N. Cardiac tamponade secondary to haemopericardium in a patient on warfarin. BMJ Case Rep 2010; 2010:pii: bcr01.2010.2606 doi:https:\/\/doi.org\/10.1136\/bcr.01.2010.2606.","DOI":"10.1136\/bcr.01.2010.2606"},{"key":"10.1016\/j.carrev.2021.09.010_bb0280","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1177\/1466424008096615","article-title":"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin","volume":"128","author":"Griffiths","year":"2008","journal-title":"J R Soc Promot Health"},{"key":"10.1016\/j.carrev.2021.09.010_bb0285","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1177\/0004563215599795","article-title":"Diluted thrombin time reliably measures low to intermediate plasma dabigatran concentrations","volume":"53","author":"Bo\u017ei\u010d-Mijovski","year":"2016","journal-title":"Ann Clin Biochem"},{"key":"10.1016\/j.carrev.2021.09.010_bb0290","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.jacc.2019.12.068","article-title":"Select drug-drug interactions with direct oral anticoagulants: JACC review topic of the week","volume":"75","author":"Wiggins","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carrev.2021.09.010_bb0295","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1136\/bmj.331.7516.529","article-title":"SSRIs and gastrointestinal bleeding","volume":"331","author":"Paton","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/j.carrev.2021.09.010_bb0300","doi-asserted-by":"crossref","first-page":"967","DOI":"10.2147\/TCRM.S84210","article-title":"New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events","volume":"11","author":"Mekaj","year":"2015","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.carrev.2021.09.010_bb0305","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.amjmed.2015.12.025","article-title":"Efficacy and safety of rivaroxaban in patients with venous thromboembolism and active malignancy: a single-center registry","volume":"129","author":"Bott-Kitslaar","year":"2016","journal-title":"Am J Med"}],"container-title":["Cardiovascular Revascularization Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553838921006722?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553838921006722?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:23:43Z","timestamp":1761560623000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1553838921006722"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":61,"alternative-id":["S1553838921006722"],"URL":"https:\/\/doi.org\/10.1016\/j.carrev.2021.09.010","relation":{},"ISSN":["1553-8389"],"issn-type":[{"value":"1553-8389","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hemopericardium in the Setting of Direct Oral Anticoagulant Use: An Updated Systematic Review","name":"articletitle","label":"Article Title"},{"value":"Cardiovascular Revascularization Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.carrev.2021.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}